SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA GENETICS reported Q3 2026 revenue of $24.3 million, up 25% year over year, while its adjusted EBITDA loss narrowed 31% to $6.1 million. Liquid Biopsy analysis volume more than doubled year over year, and management expects 2026 revenue at the upper end of its $94 million–$96 million guidance range; it reaffirmed a full-year adjusted EBITDA loss forecast of $29 million–$32 million and expects positive adjusted EBITDA in the second half of 2027. Management cited foreign-exchange pressure as a potential Q4 revenue headwind, while U.K. Guardant Health proceedings remain ongoing and generated $931,000 of Q3 net legal expense.

Analysis

The important signal is not volume growth alone; it is whether SOPHiA can turn newly signed accounts into recurring, paid utilization without rebuilding its cost base. The implementation backlog creates a timing mismatch: bookings support visibility, but delayed validation can defer revenue and strain customer-facing capacity. Management’s 2027 coverage claim is not equivalent to recognized revenue, so conversion rates and time-to-go-live matter more than pipeline size.

If hospitals bring more sequencing in-house, value can shift from centralized testing providers toward platform vendors and local labs. SOPHiA’s lower-cost workflow may widen adoption, but the model still depends on reimbursement, lab execution and clinician use—not just software demand. AZN’s decentralized CDx programs could benefit if distributed testing improves treatment selection and access; they remain development programs, not evidence of commercial contribution. MYGN’s contribution to the prostate program is a potential capability signal, not yet proof of material revenue.

The legal outcome reduces near-term injunction risk to SOPHiA’s MSK-ACCESS commercialization in the relevant UPC proceeding, but UK claims and legal costs remain an overhang. Do not extrapolate this to a resolution of all disputes or to GH’s broader business. Over 1–3 months, track Q4 FX, account ramp and backlog conversion. Over 6–18 months, the key test is whether growth persists alongside improving margins and the stated profitability timeline. The contrarian risk to the optimistic narrative: signed demand may be counted well before it becomes productive usage, while selective commercial and medical-affairs spending could temper operating leverage.

Key Decisions for Investors

• SOPH: constructive, but avoid chasing a post-earnings gap without valuation and price-action context. Consider a staged long only if subsequent reporting shows new-account activation translating into revenue and gross margin holding or improving; reduce or exit if backlog conversion slows or profitability milestones slip.
• Set a 1–3 month alert on implementation timing, analysis growth versus revenue growth, and Q4 reported versus constant-currency performance. A widening gap between signed accounts/volume and revenue, or a material FX-driven guidance reduction, would weaken the thesis.
• Treat the AZN–SOPHiA CDx relationship as strategic optionality, not a near-term AZN earnings catalyst. Reassess only on disclosed validation, regulatory or commercialization milestones; the supplied information does not support a standalone AZN trade.
• GH litigation is a watch item, not a directional pair trade: monitor remaining UK proceedings, injunction developments and SOPHiA’s legal expense trend. A material adverse ruling or renewed restriction on MSK-ACCESS would falsify the reduced near-term legal-risk view.